4//SEC Filing
Patton Cynthia M 4
Accession 0001127602-19-027930
CIK 0000318154other
Filed
Sep 3, 8:00 PM ET
Accepted
Sep 4, 6:07 PM ET
Size
17.3 KB
Accession
0001127602-19-027930
Insider Transaction Report
Form 4
AMGEN INCAMGN
Patton Cynthia M
SVP & CCO
Transactions
- Sale
Common Stock
2019-08-30$208.07/sh−2,875$598,193→ 26,899 total - Exercise/Conversion
Common Stock
2019-08-30$156.35/sh+5,749$898,856→ 32,648 total - Exercise/Conversion
Nqso (Right to Buy)
2019-08-30−2,875→ 5,839 totalExercise: $162.60From: 2019-05-01Exp: 2027-05-01→ Common Stock (2,875 underlying) - Sale
Common Stock
2019-08-30$208.07/sh−5,749$1,196,178→ 26,899 total - Exercise/Conversion
Common Stock
2019-08-30$162.60/sh+2,875$467,475→ 29,774 total - Sale
Common Stock
2019-08-30$208.07/sh−4,802$999,139→ 22,097 total - Exercise/Conversion
Nqso (Right to Buy)
2019-08-30−5,749→ 2,962 totalExercise: $156.35From: 2018-05-03Exp: 2026-05-03→ Common Stock (5,749 underlying)
Holdings
- 264.49(indirect: By 401(k))
Common Stock
Footnotes (6)
- [F1]The price reported is an average price. The prices ranged from $207.425 to $208.520 per share for this cashless exercise of 5,749 stock options expiring May 3, 2026. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
- [F2]The price reported is an average price. The prices ranged from $207.425 to $208.520 per share for this cashless exercise of 2,875 stock options expiring May 1, 2027. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
- [F3]The price reported is an average price. The prices ranged from $207.425 to $208.520 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
- [F4]These shares include the following RSUs granted under the Company's equity plans: 348 RSUs which vest on 5/3/2020; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 901 RSUs which vest in installments of 297 on 4/27/2020, 297 on 4/27/2021 and 307 on 4/27/2022; and 902 RSUs which will vest in installments of 297 on 5/3/2021, 298 on 5/3/2022 and 307 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- [F5]These shares include 116 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
- [F6]These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.
Documents
Issuer
AMGEN INC
CIK 0000318154
Entity typeother
Related Parties
1- filerCIK 0001560565
Filing Metadata
- Form type
- 4
- Filed
- Sep 3, 8:00 PM ET
- Accepted
- Sep 4, 6:07 PM ET
- Size
- 17.3 KB